Nirsevimab & COVID-19 Vaccine Availability

logo

To: Maine Immunization Program Providers

From: Maine Immunization Program

Subject: Nirsevimab & COVID-19 Vaccine Availability

Date: November 7, 2024

 

The Maine Immunization Program (MIP) would like to take a moment to ensure all enrolled Vaccines for Children (VFC) providers have full access to nirsevimab and COVID-19 vaccines during this 2024-2025 respiratory season. Nirsevimab and all COVID-19 vaccine presentations are available to order through ImmPact and are excluded from MIP’s wastage policy. Replacement is not required for any nirsevimab or COVID-19 vaccine doses. As you place your orders during the respiratory season, please be mindful to not over order to prevent unnecessary waste. 

At this time, MIP is encouraging all VFC enrolled provider locations to order nirsevimab (50 mg and 100 mg) and COVID-19 vaccines based on patient population.  MIP’s goal is for nirsevimab and COVID-19 vaccine to be widely available across Maine at all enrolled VFC provider locations to ensure eligible children are not being turned away due to lack of vaccine inventory on site. 

Nirsevimab Vaccine Availability:

As MIP continues to receive additional allocations from the Center for Disease Control and Prevention (CDC), ordering for nirsevimab will remain open each week allowing provider sites to order the number of doses needed to accommodate their patient population throughout the Respiratory Syncytial Virus (RSV) season.

  • Nirsevimab 50 mg remains available to order at a maximum quantity of 50 doses per site.
  • Nirsevimab 100 mg remains open at 75 doses per site.

**All orders for nirsevimab MUST be placed separate from regular vaccine orders.

Orders placed with other vaccines in ImmPact will be denied.

Nirsevimab Recommended Dosage:

  • Neonates and infants born during or entering their first RSV season:
    • 50 mg if less than 5 kg (11 lbs.) in body weight
    • 100 mg if greater than or equal to 5 kg (11 lbs.) in body weight
  • Children up to 24 months of age who remain vulnerable through their second RSV season:
    • 200 mg (2 x 100 mg injections)

Nirsevimab Documentation Requirements:

  • All administered doses of nirsevimab must be entered into an infant’s ImmPact record within    5 days of administration to prevent vaccination errors.

COVID-19 Vaccine Availability:

As a VFC enrolled provider site, it is required to have COVID-19 vaccines on hand or a workplan with partnering locations to ensure the vaccine is made available and the child is not turned away. 

All three presentations of COVID-19 vaccines (Pfizer, Moderna, and Novavax) are available to order through ImmPact.

The following COVID-19 vaccine presentations are available for order:

  • Spikevax 12+ - NDC # 80777-0110-93
  • Moderna 6m-11yrs – NDC # 80777-0291-80
  • Pfizer 5-11yrs – NDC # 59267-4438-02
  • Pfizer 6m-4yrs – NDC # 59267-4426-02
  • Comirnaty 12+ - NDC # - 00069-2432-10
  • Novavax 12+ - NDC # - 80631-0107-10

For the most up to date COVID-19 vaccine clinical guidance, please reference Clinical Guidance for COVID-19 Vaccination | CDC

For questions, contact the Maine Immunization Program at ImmunizeME.DHHS@maine.gov or call 207-287-3746.

Thank you for your continued commitment to keeping Mainer’s safe from vaccine preventable disease